Time-Restricted Eating May Boost Multiple Myeloma Treatment Response
A randomized feasibility trial tests 16:8 intermittent fasting alongside standard myeloma therapy to improve chemosensitivity and treatment outcomes.
Summary
The FASTINA trial is a randomized feasibility study testing whether a 16:8 time-restricted eating (TRE) protocol, combined with nutritional counseling, can enhance response to standard multiple myeloma (MM) therapy. Multiple myeloma is an incurable blood cancer prone to relapse, and preclinical research suggests fasting-related metabolic shifts may make cancer cells more vulnerable to treatment. Fifty-four adults with MM will be randomized to either TRE plus nutritional counseling or counseling alone for 12 weeks. The primary goals are confirming patient adherence and measuring complete response with measurable residual disease negativity. Secondary endpoints include survival, quality of life, body composition, and safety. This is the first formal trial of TRE in a blood cancer population and aims to inform whether a larger efficacy trial is warranted.
Detailed Summary
Multiple myeloma is an incurable plasma cell cancer characterized by inevitable relapse and progressively shorter response durations with each treatment cycle. New strategies to enhance chemosensitivity without increasing toxicity are urgently needed, and dietary interventions have emerged as a promising, low-cost adjunct to standard oncology care.
Preclinical evidence suggests that time-restricted eating (TRE) induces metabolic changes — including reduced insulin and IGF-1 signaling, increased autophagy, and altered nutrient availability — that may selectively stress cancer cells while protecting normal tissues. Clinical trials in solid tumors, particularly breast cancer, have offered early signals of feasibility and possible toxicity reduction, but data in hematological malignancies remain entirely absent.
FASTINA (Fasting in Staging of MM – Intervention for Nutritional Adherence) is a single-center, open-label, parallel-group randomized controlled feasibility trial registered in Germany. Fifty-four adults with multiple myeloma will be randomized 1:1 to 16:8 TRE plus nutritional counseling versus nutritional counseling alone for 12 weeks during active systemic therapy. The 16:8 protocol restricts food intake to an 8-hour daily window, which is one of the most clinically practical fasting regimens.
Primary endpoints are dual: dietary adherence of at least 80%, and complete response with measurable residual disease (MRD) negativity at the end of treatment — a robust surrogate for long-term outcomes in myeloma. Secondary endpoints encompass overall response rates, nutritional status, body composition, grade 3 or higher adverse events, progression-free survival, overall survival, quality of life, and fatigue.
If feasibility and preliminary safety are confirmed, FASTINA is designed to power a subsequent phase II efficacy trial. This study is notable as the first structured test of TRE in a hematologic cancer population, and its results could open a new dietary adjunct strategy with broad implications for cancer-care longevity research. Limitations include the single-center design and abstract-only availability of detailed methodology.
Key Findings
- 16:8 TRE is being tested as an adjunct to myeloma chemotherapy to exploit cancer cell sensitivity to nutrient deprivation.
- Primary endpoints combine dietary adherence (≥80%) and MRD-negative complete response — a strong prognostic marker.
- This is the first randomized trial of time-restricted eating in any hematological malignancy.
- Preclinical data suggest TRE may enhance chemosensitivity via reduced IGF-1, increased autophagy, and metabolic stress on tumor cells.
- Safety endpoints include grade 3+ adverse events, nutritional status, and body composition to monitor for harm during active cancer treatment.
Methodology
FASTINA is a single-center, open-label, parallel-group randomized controlled feasibility trial (n=54) conducted at University Hospital Schleswig-Holstein, Germany. Participants are randomized 1:1 to 16:8 TRE plus nutritional counseling or counseling alone for 12 weeks during active systemic myeloma therapy. The trial is registered under DRKS00034370.
Study Limitations
The summary is based on the abstract only, as the full protocol paper was not accessible. The trial is single-center and small (n=54), designed primarily for feasibility rather than definitive efficacy conclusions. Open-label design introduces potential bias, and results will be hypothesis-generating rather than practice-changing on their own.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: